Lisata Therapeutics (LSTA) Competitors $2.47 -0.04 (-1.59%) Closing price 04:00 PM EasternExtended Trading$2.46 -0.01 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. PLRX, IZTC, HOWL, IFRX, WHWK, MGX, ENTX, QNCX, APLT, and IMUXShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Pliant Therapeutics (PLRX), Invizyne Technologies (IZTC), Werewolf Therapeutics (HOWL), InflaRx (IFRX), Whitehawk Therapeutics (WHWK), Metagenomi (MGX), Entera Bio (ENTX), Quince Therapeutics (QNCX), Applied Therapeutics (APLT), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors Pliant Therapeutics Invizyne Technologies Werewolf Therapeutics InflaRx Whitehawk Therapeutics Metagenomi Entera Bio Quince Therapeutics Applied Therapeutics Immunic Lisata Therapeutics (NASDAQ:LSTA) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Do institutionals and insiders hold more shares of LSTA or PLRX? 8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer LSTA or PLRX? In the previous week, Lisata Therapeutics had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Lisata Therapeutics and 0 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.00 beat Lisata Therapeutics' score of -0.19 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lisata Therapeutics Neutral Pliant Therapeutics Neutral Which has more volatility and risk, LSTA or PLRX? Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Is LSTA or PLRX more profitable? Lisata Therapeutics' return on equity of -69.68% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -69.68% -59.44% Pliant Therapeutics N/A -73.45%-55.66% Which has higher valuation and earnings, LSTA or PLRX? Lisata Therapeutics has higher revenue and earnings than Pliant Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M21.64-$19.99M-$2.23-1.11Pliant TherapeuticsN/AN/A-$210.30M-$3.40-0.44 Do analysts recommend LSTA or PLRX? Lisata Therapeutics presently has a consensus target price of $23.50, suggesting a potential upside of 851.42%. Pliant Therapeutics has a consensus target price of $8.19, suggesting a potential upside of 453.21%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Lisata Therapeutics is more favorable than Pliant Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Pliant Therapeutics 1 Sell rating(s) 12 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryLisata Therapeutics beats Pliant Therapeutics on 9 of the 14 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.64M$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-1.1121.5485.6826.86Price / Sales21.64428.10583.23185.42Price / CashN/A46.3226.3031.10Price / Book0.7110.0613.256.72Net Income-$19.99M-$52.22M$3.30B$276.44M7 Day Performance-5.73%5.84%4.70%3.13%1 Month Performance13.82%12.04%8.43%10.21%1 Year Performance-17.39%26.13%88.01%40.35% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.3619 of 5 stars$2.47-1.6%$23.50+851.4%-16.4%$21.64M$1M-1.1130Gap DownPLRXPliant Therapeutics3.7983 of 5 stars$1.48-0.7%$8.19+453.2%-87.1%$90.86M$1.58M-0.4490IZTCInvizyne TechnologiesN/A$14.50-6.3%N/AN/A$90.65MN/A0.0029HOWLWerewolf Therapeutics3.1197 of 5 stars$1.97-10.0%$8.00+306.1%+0.0%$90.09M$1.88M-1.2040High Trading VolumeIFRXInflaRx2.4843 of 5 stars$1.34-2.2%$6.20+362.7%-3.2%$89.95M$180K-1.6760Positive NewsShort Interest ↑Gap UpWHWKWhitehawk TherapeuticsN/A$1.90-1.0%N/AN/A$89.54M$21.60M-31.6721Positive NewsMGXMetagenomi3.4668 of 5 stars$2.37+3.0%$10.00+321.9%+33.2%$88.95M$52.29M-1.00236ENTXEntera Bio1.6231 of 5 stars$1.92-1.5%$10.00+420.8%-1.6%$87.67M$180K-7.3820Positive NewsQNCXQuince Therapeutics3.3407 of 5 stars$1.63+1.2%$8.14+399.6%+147.3%$87.55MN/A-1.5060APLTApplied Therapeutics3.6649 of 5 stars$0.60-1.1%$4.13+581.9%-86.8%$87.11M$460K-1.3430IMUXImmunic2.5054 of 5 stars$0.88-5.7%$9.50+977.6%-41.6%$86.97MN/A-0.9470Gap Up Related Companies and Tools Related Companies Pliant Therapeutics Competitors Invizyne Technologies Competitors Werewolf Therapeutics Competitors InflaRx Competitors Whitehawk Therapeutics Competitors Metagenomi Competitors Entera Bio Competitors Quince Therapeutics Competitors Applied Therapeutics Competitors Immunic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
